Roche Holding Stock Price, News & Analysis (OTCMKTS:RHHBY)

$31.60 -0.06 (-0.19 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$31.60
Today's Range$31.35 - $31.76
52-Week Range$25.25 - $36.82
Volume1.14 million shs
Average Volume2.00 million shs
Market Capitalization$216.75 billion
P/E RatioN/A
Dividend Yield3.25%
Beta0.64

About Roche Holding (OTCMKTS:RHHBY)

Roche Holding logoRoche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Receive RHHBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:RHHBY
CUSIPN/A
Phone+41-9-732354295

Debt

Debt-to-Equity Ratio0.66%
Current Ratio1.29%
Quick Ratio0.92%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio15.96
P/E Growth2.28

Sales & Book Value

Annual Sales$49.58 billion
Price / Sales4.34
Cash Flow$1.80 per share
Price / Cash17.60
Book Value$3.93 per share
Price / Book8.04

Profitability

Trailing EPS$1.43
Net Income$9.72 billion
Net Margins21.17%
Return on Equity46.76%
Return on Assets14.96%

Miscellaneous

Employees94,052
Outstanding Shares6,815,420,000

Frequently Asked Questions for Roche Holding (OTCMKTS:RHHBY)

What is Roche Holding's stock symbol?

Roche Holding trades on the OTCMKTS under the ticker symbol "RHHBY."

Where is Roche Holding's stock going? Where will Roche Holding's stock price be in 2017?

11 analysts have issued twelve-month target prices for Roche Holding's shares. Their forecasts range from $38.00 to $38.00. On average, they anticipate Roche Holding's share price to reach $38.00 in the next twelve months. View Analyst Ratings for Roche Holding.

Who are some of Roche Holding's key competitors?

Who are Roche Holding's key executives?

Roche Holding's management team includes the folowing people:

  • Severin Schwan, Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director (Age 50)
  • Alan Hippe, Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer (Age 50)
  • Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications (Age 55)
  • Sophie Kornowski-Bonnet, Member of the Enlarged Corporate Executive Committee, Head Roche Partnering (Age 54)
  • Osamu Nagayama, Member of the Enlarged Corporate Executive Committee, Chairman and Chief Executive Officer Chugai (Age 70)
  • John C. Reed M.D., Ph.D., Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development (Age 59)
  • Michael David Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development (Age 59)
  • Cristina A. Wilbur, Member of the Executive Committee, Head Group Human Resources (Age 50)
  • Urs Jaisli, Chief Compliance Officer (Age 61)
  • Gottlieb A. Keller, Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors (Age 63)

Who owns Roche Holding stock?

Roche Holding's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Lenox Wealth Management Inc. (0.00%), Associated Banc Corp (0.00%), Sterling Capital Management LLC (0.00%), Patten Group Inc. (0.00%), Granahan Investment Management Inc. MA (0.00%) and Stonebridge Capital Advisors LLC (0.00%). View Institutional Ownership Trends for Roche Holding.

Who sold Roche Holding stock? Who is selling Roche Holding stock?

Roche Holding's stock was sold by a variety of institutional investors in the last quarter, including Associated Banc Corp and Granahan Investment Management Inc. MA. View Insider Buying and Selling for Roche Holding.

Who bought Roche Holding stock? Who is buying Roche Holding stock?

Roche Holding's stock was acquired by a variety of institutional investors in the last quarter, including Lenox Wealth Management Inc., Stonebridge Capital Advisors LLC, Patten Group Inc. and Sterling Capital Management LLC. View Insider Buying and Selling for Roche Holding.

How do I buy Roche Holding stock?

Shares of Roche Holding can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Roche Holding's stock price today?

One share of Roche Holding stock can currently be purchased for approximately $31.60.

How big of a company is Roche Holding?

Roche Holding has a market capitalization of $216.75 billion and generates $49.58 billion in revenue each year. The company earns $9.72 billion in net income (profit) each year or $1.43 on an earnings per share basis. Roche Holding employs 94,052 workers across the globe.

How can I contact Roche Holding?

Roche Holding's mailing address is Grenzacherstr. 124, BASEL, 4058, Switzerland. The company can be reached via phone at +41-9-732354295 or via email at [email protected]


MarketBeat Community Rating for Roche Holding (RHHBY)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  168
MarketBeat's community ratings are surveys of what our community members think about Roche Holding and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Roche Holding (OTCMKTS:RHHBY)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.152.152.332.63
Ratings Breakdown: 2 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.00$38.00$38.00$33.37
Price Target Upside: 27.90% upside27.90% upside20.71% upside4.17% upside

Consensus Price Target History for Roche Holding (OTCMKTS:RHHBY)

Price Target History for Roche Holding (OTCMKTS:RHHBY)

Analysts' Ratings History for Roche Holding (OTCMKTS:RHHBY)

Show:
DateFirmActionRatingPrice TargetDetails
10/24/2017Berenberg BankDowngradeBuy -> HoldView Rating Details
10/18/2017Citigroup Inc.DowngradeBuy -> NeutralView Rating Details
9/26/2017BNP ParibasDowngradeNeutral -> UnderperformView Rating Details
9/19/2017Cowen IncReiterated RatingBuy$38.00View Rating Details
7/26/2017Morgan StanleyReiterated RatingOverweight -> Equal WeightView Rating Details
7/7/2017Deutsche Bank AGDowngradeBuy -> HoldView Rating Details
6/30/2017Societe GeneraleDowngradeBuy -> HoldView Rating Details
3/9/2017Liberum CapitalInitiated CoverageHold -> HoldView Rating Details
3/7/2017Barclays PLCInitiated CoverageOverweightView Rating Details
2/19/2017Jefferies Group LLCReiterated RatingBuyView Rating Details
12/7/2016Sanford C. BernsteinReiterated RatingOverweightView Rating Details
1/22/2016Piper Jaffray CompaniesInitiated CoverageOverweightView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History for Roche Holding (OTCMKTS:RHHBY)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Roche Holding (OTCMKTS:RHHBY)
Current Year EPS Consensus Estimate: $1.98 EPS
Next Year EPS Consensus Estimate: $2.08 EPS

Dividends

Dividend History for Roche Holding (OTCMKTS:RHHBY)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Roche Holding (OTCMKTS RHHBY)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Roche Holding (OTCMKTS RHHBY)

Source:
DateHeadline
Roche Sues Pfizer to Bar Biosimilar of Cancer Drug HerceptinRoche Sues Pfizer to Bar Biosimilar of Cancer Drug Herceptin
finance.yahoo.com - November 22 at 7:06 AM
Roche: The Big Pipeline PayoffRoche: The Big Pipeline Payoff
finance.yahoo.com - November 21 at 9:48 AM
Is Shire Bleeding Out?Is Shire Bleeding Out?
finance.yahoo.com - November 21 at 9:48 AM
Roches Two Good-News Scoops May Have a Short Shelf LifeRoche's Two Good-News Scoops May Have a Short Shelf Life
finance.yahoo.com - November 21 at 9:48 AM
Why Roche Cancer Trial Is Kick In The Teeth For Dow Stock MerckWhy Roche Cancer Trial Is Kick In The Teeth For Dow Stock Merck
finance.yahoo.com - November 21 at 9:48 AM
Why Keytruda Could Boost Merck’s Revenue Growth in 2018Why Keytruda Could Boost Merck’s Revenue Growth in 2018
finance.yahoo.com - November 21 at 9:48 AM
Roche Holding AG (RHHBY) Given Consensus Rating of "Hold" by AnalystsRoche Holding AG (RHHBY) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - November 20 at 3:46 PM
Phase III IMpower150 Study Showed Genentech’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) Plus Chemotherapy Significantly Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Lung CancerPhase III IMpower150 Study Showed Genentech’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) Plus Chemotherapy Significantly Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Lung Cancer
finance.yahoo.com - November 20 at 9:03 AM
Genentech’s HEMLIBRA (emicizumab-kxwh) Significantly Reduced Bleeds in Phase III Study in Hemophilia AGenentech’s HEMLIBRA (emicizumab-kxwh) Significantly Reduced Bleeds in Phase III Study in Hemophilia A
finance.yahoo.com - November 20 at 9:03 AM
Two Experimental Roche Drugs Succeed in Key Patient StudiesTwo Experimental Roche Drugs Succeed in Key Patient Studies
finance.yahoo.com - November 20 at 9:03 AM
Roche Stock Surges on Trial Successes in Cancer, HaemophiliaRoche Stock Surges on Trial Successes in Cancer, Haemophilia
finance.yahoo.com - November 20 at 9:03 AM
Roche shares climb after trial wins in cancer, haemophiliaRoche shares climb after trial wins in cancer, haemophilia
finance.yahoo.com - November 20 at 9:02 AM
Roche Cancer Drug Rises To Challenge Merck, Bristol-MyersRoche Cancer Drug Rises To Challenge Merck, Bristol-Myers
finance.yahoo.com - November 20 at 9:02 AM
Cancer Space Update: Label Expansion for Three Major Drugs - NasdaqCancer Space Update: Label Expansion for Three Major Drugs - Nasdaq
www.nasdaq.com - November 18 at 11:23 AM
Roche launches DISCOVERY Teal HRP chromogen detection kit to advance tissue-based cancer researchRoche launches DISCOVERY Teal HRP chromogen detection kit to advance tissue-based cancer research
finance.yahoo.com - November 18 at 11:23 AM
FDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular LymphomaFDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular Lymphoma
finance.yahoo.com - November 18 at 11:23 AM
FDA backs Roches Gazyva in first-line follicular lymphomaFDA backs Roche's Gazyva in first-line follicular lymphoma
finance.yahoo.com - November 18 at 11:23 AM
ADDING MULTIMEDIA FDA Approves Genentech’s HEMLIBRA (emicizumab-kxwh) for Hemophilia A with InhibitorsADDING MULTIMEDIA FDA Approves Genentech’s HEMLIBRA (emicizumab-kxwh) for Hemophilia A with Inhibitors
finance.yahoo.com - November 18 at 11:23 AM
Roche haemophilia drug wins FDA nod, with a warningRoche haemophilia drug wins FDA nod, with a warning
finance.yahoo.com - November 18 at 11:23 AM
Shire Gets Positive CHMP Opinion for Hemophilia A Drug - NasdaqShire Gets Positive CHMP Opinion for Hemophilia A Drug - Nasdaq
www.nasdaq.com - November 14 at 3:29 PM
Shire Gets Positive CHMP Opinion for Hemophilia A DrugShire Gets Positive CHMP Opinion for Hemophilia A Drug
finance.yahoo.com - November 14 at 3:29 PM
Roche receives FDA clearance for the VENTANA MMR IHC Panel for patients diagnosed with colorectal cancerRoche receives FDA clearance for the VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer
finance.yahoo.com - November 14 at 3:29 PM
Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat - NasdaqMerck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat - Nasdaq
www.nasdaq.com - November 12 at 12:20 PM
Roche MS drug Ocrevus wins European panel backingRoche MS drug Ocrevus wins European panel backing
finance.yahoo.com - November 12 at 12:20 PM
Roche MS drug Ocrevus wins European panel backingRoche MS drug Ocrevus wins European panel backing
finance.yahoo.com - November 12 at 12:20 PM
Seattle Genetics and Astellas launch early-stage study of enfortumab vedotin in urothelial cancerSeattle Genetics and Astellas launch early-stage study of enfortumab vedotin in urothelial cancer
seekingalpha.com - November 9 at 12:29 PM
PTC Therapeutics Is Still A Short: Update Post CRLPTC Therapeutics Is Still A Short: Update Post CRL
seekingalpha.com - November 1 at 3:44 PM
Can Pharma Succeed In A Condition Impacting 1 In 68 Children?Can Pharma Succeed In A Condition Impacting 1 In 68 Children?
seekingalpha.com - October 31 at 8:43 AM
Whats in the Offing for Exelixis (EXEL) in Q3 Earnings?What's in the Offing for Exelixis (EXEL) in Q3 Earnings?
finance.yahoo.com - October 27 at 7:27 PM
FDA Accepts Genentechs Supplemental Biologics License Application For Avastin As A Front-Line Treatment For Women With Advanced Ovarian CancerFDA Accepts Genentech's Supplemental Biologics License Application For Avastin As A Front-Line Treatment For Women With Advanced Ovarian Cancer
www.thestreet.com - October 27 at 7:27 PM
Genentech: FDA Accepts Supplemental Biologics License Application For AvastinGenentech: FDA Accepts Supplemental Biologics License Application For Avastin
www.rttnews.com - October 27 at 7:27 PM
Your Daily Pharma Scoop: Roches Investment Potential, Sarepta Lifts Guidance, Pfizer Restructuring - Seeking AlphaYour Daily Pharma Scoop: Roche's Investment Potential, Sarepta Lifts Guidance, Pfizer Restructuring - Seeking Alpha
seekingalpha.com - October 27 at 2:24 PM
Roche: Buying The Dip - Seeking AlphaRoche: Buying The Dip - Seeking Alpha
seekingalpha.com - October 27 at 2:24 PM
BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric CancerBioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer
www.zacks.com - October 20 at 4:00 PM
The Market Is Skeptical About Roche Ahead Of Major Trial Read-OutsThe Market Is Skeptical About Roche Ahead Of Major Trial Read-Outs
seekingalpha.com - October 20 at 4:00 PM
Roche Holding Enters Oversold Territory (RHHBY) - NasdaqRoche Holding Enters Oversold Territory (RHHBY) - Nasdaq
www.nasdaq.com - October 19 at 3:56 PM
Roche Q3 top line up 5%, guidance confirmedRoche Q3 top line up 5%, guidance confirmed
seekingalpha.com - October 19 at 8:09 AM
Roche 9-month Group Sales Rise; Confirms FY17 Forecast - Quick FactsRoche 9-month Group Sales Rise; Confirms FY17 Forecast - Quick Facts
www.nasdaq.com - October 19 at 8:09 AM
Halozyme launches early-stage study of PEGPH20 + Tecentriq in bile duct and gallbladder cancers; shares up 2%Halozyme launches early-stage study of PEGPH20 + Tecentriq in bile duct and gallbladder cancers; shares up 2%
seekingalpha.com - October 17 at 6:46 AM
3 Things In Biotech You Should Learn Today: October 14, 20173 Things In Biotech You Should Learn Today: October 14, 2017
seekingalpha.com - October 15 at 6:29 AM
Roche And Allergan: Approaches To Alzheimers - Seeking AlphaRoche And Allergan: Approaches To Alzheimer's - Seeking Alpha
seekingalpha.com - October 14 at 7:22 AM
Roche (RHHBY) Receives FDA Approval For Cobas Zika Test - NasdaqRoche (RHHBY) Receives FDA Approval For Cobas Zika Test - Nasdaq
www.nasdaq.com - October 10 at 6:22 AM
Allergans sNDA for Anti-Infective Avycaz Accepted by FDAAllergan's sNDA for Anti-Infective Avycaz Accepted by FDA
www.nasdaq.com - October 3 at 11:39 AM
How Roche Is Shoring Up Against The Biosimilar WaveHow Roche Is Shoring Up Against The Biosimilar Wave
seekingalpha.com - October 3 at 11:39 AM
ZGNX Leaps On Trial Data, NVO Gets It Right The 2nd Time, MNKD On WatchZGNX Leaps On Trial Data, NVO Gets It Right The 2nd Time, MNKD On Watch
www.rttnews.com - October 2 at 9:54 AM
3 Things In Biotech You Should Learn Today: October 2, 20173 Things In Biotech You Should Learn Today: October 2, 2017
seekingalpha.com - October 2 at 9:54 AM
Roche (RHHBY) Reports FDA Grants Priority Review for Genentechs Perjeta for Adjuvant Treatment of HER2-Positive ... - StreetInsider.comRoche (RHHBY) Reports FDA Grants Priority Review for Genentech's Perjeta for Adjuvant Treatment of HER2-Positive ... - StreetInsider.com
www.streetinsider.com - October 1 at 10:12 AM
FDA Grants Priority Review for Genentech’s Perjeta (Pertuzumab) for Adjuvant Treatment of HER2-Positive Early Breast CancerFDA Grants Priority Review for Genentech’s Perjeta (Pertuzumab) for Adjuvant Treatment of HER2-Positive Early Breast Cancer
www.businesswire.com - September 29 at 11:42 AM
Allergan (AGN) Pipeline & New Drugs to Counter Generic WoesAllergan (AGN) Pipeline & New Drugs to Counter Generic Woes
finance.yahoo.com - September 29 at 11:41 AM
Genentech: FDA Grants Priority Review For Perjeta With Herceptin, ChemotherapyGenentech: FDA Grants Priority Review For Perjeta With Herceptin, Chemotherapy
www.nasdaq.com - September 29 at 11:41 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Roche Holding (OTCMKTS RHHBY) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.